Myeloid-Derived Suppressor Cells (MDSCs): Key Regulators of Immune Suppression in Cancer

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immune cells that play a crucial role in the suppression of immune responses, particularly in the context of cancer. These cells are a major player in creating an immunosuppressive microenvironment, facilitating tumor growth, and hindering the effectiveness of cancer immunotherapies. In this article, we will explore the biology of MDSCs, their role in cancer, and the therapeutic strategies aimed at targeting these cells.

What Are Myeloid-Derived Suppressor Cells?

MDSCs are a diverse group of immature myeloid cells that accumulate in large numbers in the peripheral blood, bone marrow, and tumor microenvironment of cancer patients. These cells are characterized by their ability to suppress T-cell activation and inhibit the immune response, making them a significant contributor to tumor immune evasion. MDSCs can be broadly classified into two subpopulations based on their phenotype and function:

  1. Granulocytic (or polymorphonuclear) MDSCs (G-MDSCs): These resemble neutrophils and are typically characterized by CD11b+ and Gr-1+ markers in mice, or CD15+ and CD33+ in humans. G-MDSCs are often associated with high levels of reactive oxygen species (ROS) and the ability to suppress T-cell responses via arginase-1, inducible nitric oxide synthase (iNOS), and other mechanisms.
  2. Monocytic MDSCs (M-MDSCs): These resemble monocytes and are usually characterized by CD11b+ and Ly6C+ in mice, or CD14+ and HLA-DR- in humans. M-MDSCs suppress T-cell responses through mechanisms such as the secretion of cytokines like IL-10 and TGF-β, and by expressing immune checkpoint molecules like PD-L1.

The Role of MDSCs in Cancer

MDSCs are critically involved in creating an immunosuppressive tumor microenvironment that helps tumors evade detection and destruction by the immune system. Their role can be summarized in several key points:

  1. Inhibition of T-cell Function: One of the primary functions of MDSCs is the suppression of T-cell activation and proliferation. They achieve this through multiple mechanisms, including the production of reactive oxygen species (ROS), nitric oxide (NO), and the depletion of critical amino acids like arginine and cysteine. This inhibits T-cell receptor (TCR) signaling, rendering T-cells less effective at recognizing and attacking tumor cells.
  2. Induction of T-cell Exhaustion: MDSCs can also contribute to T-cell exhaustion, a state in which T-cells lose their ability to function effectively. This occurs through the upregulation of immune checkpoint molecules like PD-1/PD-L1, which inhibits T-cell activation and allows tumor cells to escape immune surveillance.
  3. Promotion of Tumor Angiogenesis: MDSCs are known to secrete factors that promote the formation of new blood vessels (angiogenesis) within tumors. This is essential for tumor growth, as it provides the tumor with nutrients and oxygen, further enhancing its ability to spread and grow.
  4. Interaction with Other Immune Cells: MDSCs interact not only with T-cells but also with other immune cells like natural killer (NK) cells, dendritic cells (DCs), and macrophages. For example, MDSCs can inhibit the maturation and function of dendritic cells, impairing their ability to present antigens to T-cells and thus dampening the initiation of immune responses.
  5. Immunosuppressive Cytokine Secretion: MDSCs secrete a variety of immunosuppressive cytokines such as IL-10, TGF-β, and VEGF, which help further modulate the tumor microenvironment to favor tumor growth and immune evasion.

Mechanisms of MDSC Expansion and Activation

The accumulation of MDSCs in cancer is driven by several factors, including:

  1. Tumor-Derived Factors: Tumors produce a variety of factors such as granulocyte-macrophage colony-stimulating factor (GM-CSF), vascular endothelial growth factor (VEGF), and interleukin-6 (IL-6) that promote the recruitment and expansion of MDSCs in the tumor microenvironment.
  2. Cytokine and Chemokine Networks: The presence of cytokines and chemokines like IL-1, IL-6, GM-CSF, and CCL2 in the tumor microenvironment stimulates the proliferation and differentiation of MDSCs from myeloid progenitor cells in the bone marrow. These factors also help MDSCs migrate from the bone marrow to the tumor site.
  3. Metabolic and Hypoxic Conditions: Tumors often create an environment with limited oxygen (hypoxia), which leads to the upregulation of hypoxia-inducible factors (HIFs). These factors not only promote MDSC accumulation but also enhance their immunosuppressive functions by upregulating arginase-1 and other inhibitory molecules.

MDSCs in Cancer Progression and Therapy Resistance

The presence of MDSCs in the tumor microenvironment is strongly correlated with poor prognosis in various cancers, including lung cancer, melanoma, breast cancer, and colon cancer. MDSCs contribute to tumor progression by facilitating the following:

  1. Tumor Metastasis: MDSCs can enhance the ability of cancer cells to migrate and invade distant tissues, thereby promoting metastasis. This is partly due to their ability to induce angiogenesis and remodel the extracellular matrix (ECM).
  2. Resistance to Chemotherapy and Immunotherapy: MDSCs have been implicated in resistance to both conventional therapies (chemotherapy, radiotherapy) and immunotherapies, particularly immune checkpoint inhibitors (ICIs). Their immunosuppressive effects can inhibit the effectiveness of T-cell-based therapies by reducing the number and activity of tumor-specific T-cells.
  3. Cancer Stem Cell (CSC) Maintenance: Some studies suggest that MDSCs might play a role in maintaining cancer stem cells (CSCs) by secreting factors that promote CSC self-renewal and survival. This makes tumors more resilient and less susceptible to treatment.

Therapeutic Strategies Targeting MDSCs

Given their critical role in tumor progression and immune evasion, MDSCs have become an important therapeutic target. Several strategies are being explored to reduce MDSC accumulation or block their suppressive functions:

  1. Targeting MDSC Expansion: Drugs that block cytokines and growth factors responsible for MDSC recruitment, such as GM-CSF, VEGF, or CCL2, have shown promise in preclinical studies. Inhibitors of the VEGF pathway (e.g., bevacizumab) and CCL2/CCR2 inhibitors are being tested to reduce MDSC infiltration.
  2. Depletion of MDSCs: Some therapies aim to directly deplete MDSCs. This can be achieved through the use of monoclonal antibodies targeting surface markers on MDSCs or through agents that induce apoptosis in these cells.
  3. Reversing MDSC Suppression: Another approach is to reverse the immunosuppressive functions of MDSCs. For example, blocking the production of immunosuppressive molecules such as arginase-1, NO, and ROS can restore the function of T-cells. Small molecules or antibodies that inhibit immune checkpoints like PD-L1 on MDSCs are also being explored.
  4. Combination Therapies: Combining MDSC-targeting therapies with immune checkpoint inhibitors (ICIs) or other forms of immunotherapy has shown potential for enhancing the anti-tumor immune response. For example, inhibiting MDSC activity may enhance the efficacy of PD-1/PD-L1 inhibitors by removing an important barrier to T-cell activation.

Conclusion

Myeloid-derived suppressor cells (MDSCs) are key regulators of immune suppression in the tumor microenvironment, and their presence is associated with poor prognosis and resistance to therapy. These cells play a significant role in promoting tumor growth, metastasis, and evading immune surveillance. Targeting MDSCs through various strategies, including inhibiting their expansion, depleting them, or reversing their suppressive effects, holds promise for improving cancer treatment outcomes. As research in this field continues to evolve, MDSCs are likely to become an increasingly important target in the development of novel cancer therapies.